Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-κB and Btk. This evidence concerns the gene NFKB1 and B-cell non-Hodgkin lymphoma.